160 related articles for article (PubMed ID: 17554493)
1. Long-term infliximab treatment for Behçet's disease.
Takamoto M; Kaburaki T; Numaga J; Fujino Y; Kawashima H
Jpn J Ophthalmol; 2007; 51(3):239-40. PubMed ID: 17554493
[No Abstract] [Full Text] [Related]
2. Infliximab treatment for ocular and extraocular manifestations of Behçet's disease.
Accorinti M; Pirraglia MP; Paroli MP; Priori R; Conti F; Pivetti-Pezzi P
Jpn J Ophthalmol; 2007; 51(3):191-6. PubMed ID: 17554481
[TBL] [Abstract][Full Text] [Related]
3. Cataract surgery under infliximab therapy in a patient with Behçet's disease.
Noda E; Yamanishi S; Shiraishi A; Ohashi Y
J Ocul Pharmacol Ther; 2009 Oct; 25(5):467-70. PubMed ID: 19857109
[TBL] [Abstract][Full Text] [Related]
4. Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behcet's disease on infliximab therapy.
Keino H; Okada AA; Watanabe T; Taki W
Br J Ophthalmol; 2011 Sep; 95(9):1245-50. PubMed ID: 21183514
[TBL] [Abstract][Full Text] [Related]
5. Long-term remission of ocular and extraocular manifestations in Behçet's disease using infliximab.
Handa T; Tsunekawa H; Yoneda M; Watanabe D; Mukai T; Yamamura M; Iwaki M; Zako M
Clin Exp Rheumatol; 2011; 29(4 Suppl 67):S58-63. PubMed ID: 21968238
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Behçet's disease.
Abu El-Asrar AM; Abboud EB; Aldibhi H; Al-Arfaj A
Int Ophthalmol; 2005 Jun; 26(3):83-92. PubMed ID: 17031510
[TBL] [Abstract][Full Text] [Related]
7. Intestinal Behçet's disease: maintenance of remission with adalimumab monotherapy.
Ariyachaipanich A; Berkelhammer C; Nicola H
Inflamm Bowel Dis; 2009 Dec; 15(12):1769-71. PubMed ID: 19177427
[No Abstract] [Full Text] [Related]
8. Long-lasting remission of severe Behçet's disease after the end of infliximab therapy.
Olivieri I; Padula A; Leccese P; D'Angelo S; Giasi V
J Rheumatol; 2009 Apr; 36(4):855. PubMed ID: 19342728
[No Abstract] [Full Text] [Related]
9. Cryptococcal meningitis in a patient treated with infliximab and mycophenolate mofetil for Behcet's disease.
Kluger N; Poirier P; Guilpain P; Baixench MT; Cohen P; Paugam A
Int J Infect Dis; 2009 Sep; 13(5):e325. PubMed ID: 19157948
[No Abstract] [Full Text] [Related]
10. Regression of optic disc neovascularization in patients with Behçet's uveoretinitis after infliximab therapy.
Kawaguchi T; Sugita S; Yamada Y; Miyanaga M; Mochizuki M
J Ocul Pharmacol Ther; 2010 Dec; 26(6):627-30. PubMed ID: 21043804
[TBL] [Abstract][Full Text] [Related]
11. Behçet's ileocolitis: successful treatment with tumor necrosis factor-alpha antibody (infliximab) therapy: report of a case.
Kram MT; May LD; Goodman S; Molinas S
Dis Colon Rectum; 2003 Jan; 46(1):118-21. PubMed ID: 12544532
[TBL] [Abstract][Full Text] [Related]
12. Adalimumab for sight-threatening uveitis in Behçet's disease.
Mushtaq B; Saeed T; Situnayake RD; Murray PI
Eye (Lond); 2007 Jun; 21(6):824-5. PubMed ID: 16601736
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment of severe Behçet's disease with infliximab in an Italian Olympic athlete.
Olivieri I; Latanza L; Siringo S; Peruz G; Di Iorio V
J Rheumatol; 2008 May; 35(5):930-2. PubMed ID: 18464316
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of combination therapy of anti-TNF-α antibody infliximab and methotrexate in refractory entero-Behçet's disease.
Iwata S; Saito K; Yamaoka K; Tsujimura S; Nawata M; Hanami K; Tanaka Y
Mod Rheumatol; 2011 Apr; 21(2):184-91. PubMed ID: 21052764
[TBL] [Abstract][Full Text] [Related]
15. Clinical experience with adalimumab in the treatment of ocular Behçet disease.
Bawazeer A; Raffa LH; Nizamuddin SH
Ocul Immunol Inflamm; 2010 Jun; 18(3):226-32. PubMed ID: 20482404
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of switching to adalimumab in a patient with refractory uveitis of Behçet's disease to infliximab.
Leccese P; Latanza L; D'Angelo S; Padula A; Olivieri I
Clin Exp Rheumatol; 2011; 29(4 Suppl 67):S93. PubMed ID: 21813069
[No Abstract] [Full Text] [Related]
17. Infliximab in refractory uveitis due to Behçet's disease.
Wechsler B; Sablé-Fourtassou R; Bodaghi B; Huong DL; Cassoux N; Badelon I; Fain O; LeHoang P; Piette JC
Clin Exp Rheumatol; 2004; 22(4 Suppl 34):S14-6. PubMed ID: 15515776
[TBL] [Abstract][Full Text] [Related]
18. Anti-tumor necrosis factor alpha antibody in the treatment of Behçet's disease.
Nakamura S; Ohno S
Int Ophthalmol Clin; 2005; 45(2):179-89. PubMed ID: 15791165
[No Abstract] [Full Text] [Related]
19. Successful use of infliximab in a patient with neuro-Behçet's disease.
Abalos-Medina GM; Sánchez-Cano D; Ruiz-Villaverde G; Ruiz-Villaverde R; Quirosa Flores S; Raya Alvarez E
Int J Rheum Dis; 2009 Sep; 12(3):264-6. PubMed ID: 20374357
[TBL] [Abstract][Full Text] [Related]
20. Infliximab monotherapy in neuro-Behçet's disease: four year follow-up in a long-standing case resistant to conventional therapies.
Fasano A; D'Agostino M; Caldarola G; Feliciani C; De Simone C
J Neuroimmunol; 2011 Oct; 239(1-2):105-7. PubMed ID: 21911262
[No Abstract] [Full Text] [Related]
[Next] [New Search]
